Literature DB >> 27059391

There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS.

Aaron D Gitler1, Hitomi Tsuiji2.   

Abstract

The discovery of C9orf72 mutations as the most common genetic cause of pan class="Disease">amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has awakened a surge of interest in deciphering how mutations in this mysterious gene cause disease and what can be done to stop it. C9orf72 harbors a hexanucleotide repeat, GGGGCC, in a non-coding region of the gene and a massive expansion of this repeat causes ALS, FTD, or both (FTD/ALS). Many questions lie ahead. What does this gene normally do? What is the consequence of an enormous GGGGCC repeat expansion on that gene's function? Could that hexanucleotide repeat expansion have additional pathological actions unrelated to C9orf72 function? There has been tremendous progress on all fronts in the quest to define how C9orf72 mutations cause disease. Many new experimental models have been constructed and unleashed in powerful genetic screens. Studies in mouse and human patient samples, including iPS-derived neurons, have provided unprecedented insights into pathogenic mechanisms. Three major hypotheses have emerged and are still being hotly debated in the field. These include (1) loss of function owing to decrease in the abundance of C9orf72 protein and its ability to carryout its still unknown cellular role; (2) RNA toxicity from bidirectionally transcribed sense (GGGGCC) and antisense (GGCCCC) transcripts that accumulate in RNA foci and might sequester critical RNA-binding proteins; (3) proteotoxicity from dipeptide repeat proteins produced by an unconventional form of translation from the expanded nucleotide repeats. Here we review the evidence in favor and against each of these three hypotheses. We also suggest additional experiments and considerations that we propose will help clarify which mechanism(s) are most important for driving disease and therefore most critical for considering during the development of therapeutic interventions. This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALS, FTD; C9orf72; Dipeptide repeat protein; RNA

Mesh:

Substances:

Year:  2016        PMID: 27059391      PMCID: PMC5003651          DOI: 10.1016/j.brainres.2016.04.004

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  95 in total

1.  Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport.

Authors:  Marka van Blitterswijk; Rosa Rademakers
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

2.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

4.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety.

Authors:  F Tronche; C Kellendonk; O Kretz; P Gass; K Anlag; P C Orban; R Bock; R Klein; G Schütz
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

6.  Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration.

Authors:  Zihui Xu; Mickael Poidevin; Xuekun Li; Yujing Li; Liqi Shu; David L Nelson; He Li; Chadwick M Hales; Marla Gearing; Thomas S Wingo; Peng Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-03       Impact factor: 11.205

7.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

Authors:  L I Bruijn; M K Houseweart; S Kato; K L Anderson; S D Anderson; E Ohama; A G Reaume; R W Scott; D W Cleveland
Journal:  Science       Date:  1998-09-18       Impact factor: 47.728

8.  Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue.

Authors:  Jun-Xia Lu; Wei Qiang; Wai-Ming Yau; Charles D Schwieters; Stephen C Meredith; Robert Tycko
Journal:  Cell       Date:  2013-09-12       Impact factor: 41.582

9.  C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.

Authors:  Stephanie May; Daniel Hornburg; Martin H Schludi; Thomas Arzberger; Kristin Rentzsch; Benjamin M Schwenk; Friedrich A Grässer; Kohji Mori; Elisabeth Kremmer; Julia Banzhaf-Strathmann; Matthias Mann; Felix Meissner; Dieter Edbauer
Journal:  Acta Neuropathol       Date:  2014-08-14       Impact factor: 17.088

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  63 in total

Review 1.  Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Peter W French; Russell Ludowyke; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2018-12-05       Impact factor: 3.911

Review 2.  Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.

Authors:  Deepti Lall; Robert H Baloh
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  Cell-to-Cell Transmission of Dipeptide Repeat Proteins Linked to C9orf72-ALS/FTD.

Authors:  Thomas Westergard; Brigid K Jensen; Xinmei Wen; Jingli Cai; Elizabeth Kropf; Lorraine Iacovitti; Piera Pasinelli; Davide Trotti
Journal:  Cell Rep       Date:  2016-10-11       Impact factor: 9.423

4.  Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD.

Authors:  Hana M Odeh; James Shorter
Journal:  Emerg Top Life Sci       Date:  2020-12-11

5.  Lost & found: C9ORF72 and the autophagy pathway in ALS/FTD.

Authors:  Sandra Almeida; Fen-Biao Gao
Journal:  EMBO J       Date:  2016-05-06       Impact factor: 11.598

6.  Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72.

Authors:  Noori Chai; Michael S Haney; Julien Couthouis; David W Morgens; Alyssa Benjamin; Kathryn Wu; James Ousey; Shirleen Fang; Sarah Finer; Michael C Bassik; Aaron D Gitler
Journal:  Brain Res       Date:  2019-12-13       Impact factor: 3.252

Review 7.  RNA-mediated toxicity in C9orf72 ALS and FTD.

Authors:  Zachary T McEachin; Janani Parameswaran; Nisha Raj; Gary J Bassell; Jie Jiang
Journal:  Neurobiol Dis       Date:  2020-08-21       Impact factor: 5.996

8.  A human cellular model of amyotrophic lateral sclerosis.

Authors:  Rebecca M Marton; Sergiu P Paşca
Journal:  Nat Med       Date:  2018-03-06       Impact factor: 53.440

Review 9.  mRNP assembly, axonal transport, and local translation in neurodegenerative diseases.

Authors:  Bilal Khalil; Dmytro Morderer; Phillip L Price; Feilin Liu; Wilfried Rossoll
Journal:  Brain Res       Date:  2018-02-17       Impact factor: 3.252

Review 10.  Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.

Authors:  Alexander Starr; Rita Sattler
Journal:  Brain Res       Date:  2018-02-14       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.